Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know

Headache
Stephen David SilbersteinCen Xu

Abstract

Monoclonal antibodies (mAbs) are now an important part of the treatment armamentarium for a wide range of conditions including cancer, autoimmune diseases, inflammatory diseases of the joint and bowel, transplant rejection, and multiple sclerosis. Significant progress over the last 30 years in the development of therapeutic mAbs has resulted in improved efficacy and safety. Monoclonal antibodies approved for the treatment of neurological illnesses so far are limited to use in multiple sclerosis. Several therapeutic mAbs have completed phase 2 clinical trials for migraine prevention, and there are phase 3 trials underway for migraine prophylaxis and for cluster headache at the time of this writing. The purpose of this review is to discuss the characteristics of mAbs, including their mechanism of action and safety profile, and briefly describe the mAbs being evaluated for the prevention of migraine and cluster headaches. Monoclonal antibodies have several features that distinguish them from small molecules, including very high selectivity, relatively long half-life that generally allows for once or twice monthly dosing, and significantly reduced potential for drug-drug interactions or other nontarget related toxicities. The clini...Continue Reading

References

Nov 21, 1992·BMJ : British Medical Journal·M B LlewelynS J Russell
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Jul 7, 2000·The New England Journal of Medicine·P J Delves, I M Roitt
May 8, 2002·Cephalalgia : an International Journal of Headache·L H LassenJ Olesen
Mar 5, 2004·The New England Journal of Medicine·Dan M Roden
Mar 12, 2004·The New England Journal of Medicine·Jes OlesenUNKNOWN BIBN 4096 BS Clinical Proof of Concept Study Group
Jun 18, 2004·The New England Journal of Medicine·Panagiotis Korantzopoulos, Konstantinos Siogas
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
May 7, 2005·Nature Biotechnology·Louis M Weiner, Paul Carter
Jun 18, 2005·Brain Research. Brain Research Reviews·Theoharis C TheoharidesAphrodite Konstantinidou
Sep 29, 2005·Expert Opinion on Biological Therapy·David Ternant, Gilles Paintaud
Sep 29, 2006·Rheumatology International·Niko K BenderBernhard Heilig
Jul 17, 2007·Drug Discovery Today·Mohammad A Tabrizi, Lorin K Roskos
Jul 20, 2007·Headache·Srikanth ThalakotiPaul L Durham
Oct 5, 2007·Neurology·T W HoUNKNOWN MK-0974 Protocol 004 study group
Mar 18, 2009·Neurologic Clinics·Peter J Goadsby
Apr 7, 2009·Regulatory Toxicology and Pharmacology : RTP·Rafael PonceDan Wierda
May 23, 2009·British Journal of Pharmacology·Patrick ChamesDaniel Baty
Jan 5, 2010·Journal of Molecular Biology·Matthew J BernettGreg A Lazar
Mar 23, 2010·Nature Reviews. Drug Discovery·Trevor T HanselAndrew J T George
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Sep 22, 2010·Cephalalgia : an International Journal of Headache·Jakob Møller HansenMessoud Ashina
Oct 12, 2010·The Journal of Headache and Pain·Kim Anker Kristiansen, Lars Edvinsson
Oct 13, 2010·Annual Review of Pharmacology and Toxicology·Honghui Zhou, Mary Ann Mascelli
Mar 9, 2011·Cephalalgia : an International Journal of Headache·David J HewittTony W Ho
Nov 30, 2011·Expert Reviews in Molecular Medicine·Ann C Raddant, Andrew F Russo
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic
Aug 28, 2012·Current Opinion in Pharmacology·Nicholas A P S BussLolke de Haan
Feb 22, 2013·British Journal of Pharmacology·C S Walker, D L Hay
Aug 3, 2013·Frontiers in Immunology·André FrenzelThomas Schirrmann
Aug 24, 2013·Cephalalgia : an International Journal of Headache·Ronald MarcusTanya Z Fischer

❮ Previous
Next ❯

Citations

Jun 25, 2016·Internal and Emergency Medicine·Maria Adele GiamberardinoPaolo Martelletti
Jun 17, 2016·Expert Review of Neurotherapeutics·Andrea NegroPaolo Martelletti
Nov 15, 2018·Headache·Morris LevinEric Pearlman
Jan 20, 2018·CNS Spectrums·Stephen D Silberstein
Apr 29, 2020·Cephalalgia : an International Journal of Headache·James M MartinezSandra Garces
Sep 5, 2019·Molecular Pharmacology·Vladimir BobkovMartine J Smit
Sep 29, 2019·Headache·Claire E J CerianiStephen D Silberstein
Sep 19, 2019·Cephalalgia : an International Journal of Headache·Karl Messlinger, Antoinette MaassenVanDenBrink
Jun 3, 2021·Neurology and Therapy·Andrew BlumenfeldIra Turner
Sep 19, 2021·Expert Opinion on Drug Metabolism & Toxicology·Abimael González-HernándezCarlos M Villalón

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Progress in Medicinal Chemistry
Theresa M WilliamsChristopher A Salvatore
Sheng li ke xue jin zhan [Progress in physiology]
M Zhao, X Wang
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Sarah Vollbracht, Alan M Rapoport
© 2021 Meta ULC. All rights reserved